Patents Assigned to ZymoGenetics
  • Cytoplasmic antiproteinase-2 and cytoplasmic antiproteinase-3 and coding sequences
    Patent number: 5747645
    Abstract: Cytoplasmic Antiproteinase-2 and Cytoplasmic Antiproteinase-3 nucleic acids and serine protease inhibitor proteins encoded thereby are useful in the purification of proteins and in the treatment of inflammatory diseases and diseases involving apoptosis.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: May 5, 1998
    Assignee: ZymoGenetics, Inc.
    Inventor: Cindy A. Sprecher
  • Method for identifying a G protein coupled glutamate receptor agonist and antagonist
    Patent number: 5747267
    Abstract: Mammalian G protein coupled glutamate receptors are identified, isolated and purified. The receptors have been cloned, sequenced and expressed by recombinant means. The receptors and antibodies thereby may be used to identify agonists and antagonists of G protein coupled glutamate receptor mediated neuronal excitation, as well as in methods of diagnosis.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: May 5, 1998
    Assignees: Zymogenetics, Inc., The Board of Regents of the University of Washington
    Inventors: Eileen Ranae Mulvihill, Frederick Stamner Hagen, Khaled M. Houamed, Wolfhard Almers
  • Method for purifying thrombopoietin
    Patent number: 5744587
    Abstract: Methods of removing protein contaminants from a solution comprising thrombopoietin are disclosed. The solution is exposed to hydroxyapatite, whereby protein contaminants are bound to the hydroxyapatite and the thrombopoietin remains substantially unbound, and the unbound thrombopoietin is recovered. The use of hydroxyapatite is advantageously combined with other purification and concentration techniques, including ion-exchange chromatography, ligand affinity chromatography, hydrophobic interaction chromatography, ultrafiltration, and differential precipitation.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 28, 1998
    Assignee: ZymoGenetics, Inc.
    Inventors: Andrew R. Alaska, Jin-Jyi Chang, William Downey, John W. Forstrom, Linh Phan
  • Hexokinase promoter and assay method
    Patent number: 5741704
    Abstract: Isolated DNA molecules comprising a portion of a human hexokinase gene promoter are disclosed. The molecules comprise promoter and insulin-sensitive transcription regulatory elements. These molecules can be used within methods for detecting insulin-like activity in test substances.
    Type: Grant
    Filed: December 28, 1995
    Date of Patent: April 21, 1998
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Sherri L. Mudri
  • L-AP4 sensitive glutamate receptors
    Patent number: 5738999
    Abstract: Metabotropic receptor mGluR7 is identified and sequenced. The mGluR7 receptor subfamily mediates inhibition of transmitter release at selected glutamatergic synapses. The receptors, mGluR7-specific peptides and antibodies thereto are used to identify agonists and antagonists of G protein coupled glutamate receptor mediated neuronal transmitter release, as well as in methods of diagnosis and therapy.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: April 14, 1998
    Assignees: ZymoGenetics, Inc., State of Oregon, acting by and through the Oregon State Board of Higher Education on behalf of the Oregon Health Sciences University
    Inventors: Thomas P. Segerson, J. Mark Kinzie, Eileen R. Mulvihill, Julie A. Saugstad, Gary L. Westbrook
  • Preparation of Pichia methanolica auxotrophic mutants
    Patent number: 5736383
    Abstract: Methods for preparing Pichia methanolica cells having auxotrophic mutations are disclosed. The methods comprise the steps of (a) exposing P. methanolica cells to mutagenizing conditions, (b) culturing the cells from step (a) in a rich medium to allow mutations to become established and replicated in at least a portion of the cells, (c) culturing the cells from step (b) in a culture medium deficient in assimilable nitrogen to deplete cellular nitrogen stores, (d) culturing the cells from step (c) in a defined culture medium comprising an inorganic nitrogen source and an amount of nystatin sufficient to kill growing P. methanolica cells to select for cells having a deficiency in a nutritional gene; and (e) culturing the selected cells from step (d) in a rich culture medium.
    Type: Grant
    Filed: August 26, 1996
    Date of Patent: April 7, 1998
    Assignee: ZymoGenetics, Inc.
    Inventor: Christopher K. Raymond
  • PDGF antagonists II
    Patent number: 5731326
    Abstract: Methods for inhibiting intimal hyperplasia in the vasculature of mammals, including primates, are disclosed. The methods comprise administering to the mammal a non-peptide PDGF antagonist such as 4-(2-(N-(2-carboxamidoindole)aminoethyl)-benzenesulfonamides or sulfonylureas. The methods are useful in reducing intimal hyperplasia due to, for example, vascular injuries resulting from angioplasty, endarterectomy, reduction atherectomy or anastomosis of a vascular graft. The non-peptide PDGF antagonists may optionally be administered coordinately with heparin, whereby the coordinately administered of non-peptide PDGF antagonist and heparin are combinatorially effective in inhibiting intimal hyperplasia.
    Type: Grant
    Filed: May 29, 1996
    Date of Patent: March 24, 1998
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles E. Hart, Mark W. Orme, Kristen M. Moynihan
  • Inhibition of blood coagulation by human-kunitz-type inhibitors
    Patent number: 5728674
    Abstract: The present invention provides isolated DNA molecules comprising a DNA segment encoding novel human Kunitz-type inhibitors. Also provided are DNA constructs comprising a first DNA segment encoding a novel human Kunitz-type inhibitor wherein said first DNA segment is operably linked to additional DNA segments required for the expression for the first DNA segment, as well as host cells containing such DNA constructs and methods for producing proteins from the host cells.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: March 17, 1998
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Walt Kisiel, Donald C. Foster
  • Stable DNA constructs
    Patent number: 5723292
    Abstract: Methods are provided for producing protein products in host cells and for selecting transformed cells comprising the step of transforming the host cell with a DNA molecule comprising a gene which complements a deficiency in the host cell. The host cell is s strain having a deficiency in a function necessary for normal cell growth. The gene in the DNA molecule, such as a plasmid, which complements the deficiency serves as a selection marker whereby the growth conditions for selection may comprise a conventional complex medium.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 3, 1998
    Assignee: ZymoGenetics, Inc.
    Inventors: Glenn H. Kawasaki, Leslie Bell, Meher Irani
  • Antibodies to G protein coupled glutamate receptors
    Patent number: 5721107
    Abstract: Mammalian G protein coupled glutamate receptors are identified, isolated and purified. The receptors have been cloned, sequenced and expressed by recombinant means. The receptors and antibodies thereby may be used to identify agonists and antagonists of G protein coupled glutamate receptor mediated neuronal excitation, as well as in methods of diagnosis.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: February 24, 1998
    Assignees: The Board of Regents of the University of Washington, Zymogenetics, Inc.
    Inventors: Eileen Ranae Mulvihill, Frederick Stamner Hagen, Khaled M. Houamed, Wolfhard Almers
  • Genetic engineering of pichia methanolica
    Patent number: 5716808
    Abstract: Methods for preparing Pichia methanolica cells containing foreign DNA constructs and methods for producing foreign polypeptides in Pichia methanolica cells are disclosed. The cells are transformed with a DNA construct comprising a first DNA segment comprising a transcription promoter of a methanol-inducible P. methanolica gene, a second DNA segment encoding a higher eukaryotic polypeptide, a third DNA segment comprising a P. methanolica gene transcription terminator, and a selectable marker. For production of foreign polypeptides, the cells are cultured under conditions in which the second DNA segment is expressed, and the polypeptide encoded by the second DNA segment is recovered.
    Type: Grant
    Filed: August 26, 1996
    Date of Patent: February 10, 1998
    Assignee: ZymoGenetics, Inc.
    Inventor: Christopher K. Raymond
  • Cytoplasmic antiproteinase-2 and coding sequences
    Patent number: 5712117
    Abstract: Cytoplasmic Antiproteinase-2 and Cytoplasmic Antiproteinase-3 nucleic acids and serine protease inhibitor proteins encoded thereby are useful in the purification of proteins and in the treatment of inflammatory diseases and diseases involving apoptosis.
    Type: Grant
    Filed: February 8, 1995
    Date of Patent: January 27, 1998
    Assignee: Zymogenetics, Inc.
    Inventor: Cindy A. Sprecher
  • Cytoplasmic antiproteinase-2 and cytoplasmic antiproteinase-3 and coding sequences
    Patent number: 5710026
    Abstract: Cytoplasmic Antiproteinase-2 and Cytoplasmic Antiproteinase-3 nucleic acids and serine protease inhibitor proteins encoded thereby are useful in the purification of proteins and in the treatment of inflammatory diseases and diseases involving apoptosis.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: January 20, 1998
    Assignee: Zymogenetics, Inc.
    Inventor: Cindy A. Sprecher
  • Methods for preparing polynucleotides encoding orphan receptor ligands
    Patent number: 5705349
    Abstract: Methods for obtaining cells that produce a ligand for an orphan receptor and methods for preparing polynucleotide molecules that encode ligands for orphan receptors are disclosed. The methods utilize growth factor-dependent parent cells that are transfected with a DNA construct encoding an orphan receptor. The transfected cells are exposed to mutagenizing conditions, and the mutagenized cells are cultured under conditions in which cell survival is dependent upon autocrine growth factor production. Progeny cells are recovered and screened to identify those that produce a ligand for the orphan receptor. Polynucleotide molecules encoding the ligand can be prepared from the identified cells.
    Type: Grant
    Filed: June 15, 1995
    Date of Patent: January 6, 1998
    Assignee: ZymoGenetics, Inc.
    Inventors: Richard D. Holly, Steven K. Burkhead
  • Stable DNA constructs
    Patent number: 5700643
    Abstract: Methods are provided for producing protein products in host cells and for selecting transformed cells comprising the step of transforming the host cell with a DNA molecule comprising a gene which complements a deficiency in the host cell. The host cell is a strain having a deficiency in a function necessary for normal cell growth. The gene in the DNA molecule, such as a plasmid, which complements the deficiency serves as a selection marker whereby the growth conditions for selection may comprise a conventional complex medium.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 23, 1997
    Assignee: ZymoGenetics, Inc.
    Inventor: Glenn Kawasaki
  • Synthetic calcitonin mimetics
    Patent number: 5698672
    Abstract: The invention provides synthetic calcitonin mimetics. The mimetics of the present invention may include modifications that further enhance desired characteristics, such as oral bioavailability, while maintaining or enhancing inhibition of bone resorption. Related pharmaceutical compositions and methods are also disclosed.
    Type: Grant
    Filed: April 4, 1995
    Date of Patent: December 16, 1997
    Assignee: ZymoGenetics, Inc.
    Inventors: Virender M. Labroo, Stephanie Beigel
  • Native calcitonin mimetics
    Patent number: 5698521
    Abstract: The invention provides isolated, biologically active native calcitonin mimetics and related methods. These small 16 and 17 amino acid proteins mimic the interaction of calcitonin on its receptor, and also exhibit bone resorptive inhibiting activity.
    Type: Grant
    Filed: April 4, 1995
    Date of Patent: December 16, 1997
    Assignee: ZymoGenetics, Inc.
    Inventors: Patricia A. McKernan, Lennie Chen, Charles Petrie, James Piggott, Robert R. West, Shirley Gasper, Colin Lellis
  • Fibrin D-domain multimer prostheses and methods for their production
    Patent number: 5693098
    Abstract: Methods for coating a prosthetic surface with anti-thrombogenic, or anti-coagulant, proteins are disclosed. The methods involve contacting a surface of a prosthetic material with a composition containing multimers of fibrin degradation products. These multimers, preferably D-dimers, have cross-linked D-domains. The methods of the invention are useful for providing an anti-thrombogenic coating on prosthetic implants which are exposed to a patient's blood after implantation, for example vascular grafts and artificial heart valves.
    Type: Grant
    Filed: November 7, 1996
    Date of Patent: December 2, 1997
    Assignees: McMaster University, ZymoGenetics, Inc.
    Inventors: Fraser D. Rubens, Paul D. Bishop
  • Preparation of immortalized cells
    Patent number: 5683906
    Abstract: Cell lines have been prepared from growth suppressor gene deficient animals. The cells include immortalized precursor cells and differentiated cells such as osteoclast precursors, osteoblast precursors, megakaryocytes, osteoclasts, osteoblasts, pancreatic .alpha.-cells, pancreatic .beta.-cells, pancreatic .delta.-cells, adipocytes, macrophages, chondrocytes and hepatocytes. The cells are useful for constructing cDNA and protein libraries, screening agonists and antagonists of compounds and factors that affect metabolic pathways of specific cells and generating cell-specific antibodies.
    Type: Grant
    Filed: September 9, 1994
    Date of Patent: November 4, 1997
    Assignee: ZymoGenetics, Inc.
    Inventor: Emma E. Moore
  • Methods for identifying modulators of human calcitonin mediated metabolism
    Patent number: 5683884
    Abstract: Human calcitonin receptors have been cloned, sequenced and expressed by recombinant means. The receptors and antibodies thereto may be used in screening systems to identify agonists and antagonists of human calcitonin receptors, thereby providing means for treating and preventing abnormal bone resorption, as well as in methods of diagnosis.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: November 4, 1997
    Assignee: ZymoGenetics, Inc.
    Inventors: Emma E. Moore, Paul O. Sheppard, Rolf E. Kuestner